Maternal Metabolic Conditions and Risk for Autism and Other Neurodevelopmental Disorders
Overview
Authors
Affiliations
Objective: We examined whether metabolic conditions (MCs) during pregnancy (diabetes, hypertension, and obesity) are associated with autism spectrum disorder (ASD), developmental delays (DD), or impairments in specific domains of development in the offspring.
Methods: Children aged 2 to 5 years (517 ASD, 172 DD, and 315 controls) were enrolled in the CHARGE (Childhood Autism Risks from Genetics and the Environment) study, a population-based, case-control investigation between January 2003 and June 2010. Eligible children were born in California, had parents who spoke English or Spanish, and were living with a biological parent in selected regions of California. Children's diagnoses were confirmed by using standardized assessments. Information regarding maternal conditions was ascertained from medical records or structured interview with the mother.
Results: All MCs were more prevalent among case mothers compared with controls. Collectively, these conditions were associated with a higher likelihood of ASD and DD relative to controls (odds ratio: 1.61 [95% confidence interval: 1.10-2.37; odds ratio: 2.35 [95% confidence interval: 1.43-3.88], respectively). Among ASD cases, children of women with diabetes had Mullen Scales of Early Learning (MSEL) expressive language scores 0.4 SD lower than children of mothers without MCs (P < .01). Among children without ASD, those exposed to any MC scored lower on all MSEL and Vineland Adaptive Behavior Scales (VABS) subscales and composites by at least 0.4 SD (P < .01 for each subscale/composite).
Conclusions: Maternal MCs may be broadly associated with neurodevelopmental problems in children. With obesity rising steadily, these results appear to raise serious public health concerns.
Female reproductive health trends and autism spectrum disorder prevalence between 2000 and 2024.
Al-Salihy A Sci Rep. 2025; 15(1):8507.
PMID: 40075145 PMC: 11904183. DOI: 10.1038/s41598-025-89979-x.
Biomarkers for autism spectrum disorder: a short review.
de Sena Barbosa M, de Souza R, Goncalves Cherain L, Santos Ferreira L, Santos Affi Peixoto M, Lemos Passos M Ann Med Surg (Lond). 2024; 86(12):7227-7231.
PMID: 39649921 PMC: 11623892. DOI: 10.1097/MS9.0000000000002689.
The Microbiome-Genetics Axis in Autism Spectrum Disorders: A Probiotic Perspective.
Mihailovich M, Tolinacki M, Sokovic Bajic S, Lestarevic S, Pejovic-Milovancevic M, Golic N Int J Mol Sci. 2024; 25(22).
PMID: 39596472 PMC: 11594817. DOI: 10.3390/ijms252212407.
Dehesh T, Mosleh-Shirazi M, Jafari S, Abolhadi E, Dehesh P BMC Psychol. 2024; 12(1):685.
PMID: 39578893 PMC: 11583425. DOI: 10.1186/s40359-024-02184-9.
Bilder D, Sullivan S, Hughes M, Dalton S, Hall-Lande J, Nicholls C Autism Res. 2024; 17(11):2418-2429.
PMID: 39420702 PMC: 11568895. DOI: 10.1002/aur.3247.